Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 Mar 2023
Avascular necrosis (AVN) is considered an iatrogenic complication after treatment for progressive hip dysplasia, but research in China has revealed two characteristics associated with this condition. ossification nuclei.
Read Full NewsA trial tests whether 40Gy in 15 fractions over 3 weeks leads to more arm lymphedema than 50Gy in 25 fractions over 5 weeks.
State mandates requiring insurance coverage for additional breast cancer scans for those with dense breasts are failing to boost usage.
1.
More People Than Previously Believed Have Schizophrenia.
2.
Venetoclax Combo Shows Promise in Younger Patients With AML
3.
In NPM1-mutated acute myeloid leukemia, MRD Correlates with Allo-Transplant Benefit.
4.
Study finds primary-care doctors often overlook prostate cancer risk in Black men
5.
Characterizing metastatic disease during adaptive therapy by using dynamic biomarkers and mathematical modeling.
1.
Unlocking the Potential of Trabectedin: A Novel Therapy for Cancer Treatment
2.
ctDNA in Oncology: Transforming MRD Assessment, Disease Tracking, and Early Cancer Detection
3.
Unlocking the Mystery of Hemoglobin C Trait: A Closer Look at a Rare Blood Disorder
4.
Understanding Neutropenic Fever: What It Is and Why it's a Serious Concern
5.
All You Need To Know About Cancer Antigen 27-29: Causes, Symptoms & Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
2.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
3.
Navigating the Complexities of Ph Negative ALL - Part XIV
4.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
5.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge